Entero Therapeutics (ENTO) Stock Analysis

What Entero Therapeutics does

Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company formerly known as First Wave BioPharma, Inc. (and prior to September 2021, AzurRx BioPharma, Inc.), is dedicated to discovering and advancing localized, non-systemic treatments for various gastrointestinal conditions. Its development pipeline features several key therapeutic candidates: latiglutenase, an oral biotherapeutic formulated to break down gluten into non-immunogenic peptides for celiac disease patients; adrulipase, a recombinant lipase enzyme engineered to facilitate the digestion of fats and other nutrients; capeserod, a selective 5-HT4 receptor partial agonist aimed at addressing gastroparesis; and niclosamide, an oral small molecule with anti-inflammatory properties for individuals with inflammatory bowel diseases such as ulcerative colitis and Crohn's disease. Furthermore, the company is developing CypCel, a management tool designed to monitor the intestinal health of recovering celiac disease patients. Founded in 2014, the company's operations are based in Boca Raton, Florida.

Key metrics

ETFs linked to ENTO

Broad-market and Healthcare sector ETFs an investor holding Entero Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how ENTO fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Entero Therapeutics?

Entero Therapeutics trades under the ticker ENTO on NASDAQ.

Which exchange is ENTO listed on?

ENTO is listed on NASDAQ.

What sector does Entero Therapeutics operate in?

Entero Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze ENTO in a portfolio?

PortView shows ENTO's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.